Valsartan Induced Melanoma?! First Description in Medical Literature!
DOI:
https://doi.org/10.3889/oamjms.2018.517Keywords:
Valsartan, Cutaneous melanoma, Surgery, Drug-induced melanoma, Survival benefitAbstract
BACKGROUND: Drug-induced carcinogenesis is a matter of huge popularity and the subject of in-depth research over the last few years. According to the literature, dopamine agonists and acetylsalicylic acid fall into the list of drugs likely to potentiate the development of cutaneous melanoma. However, according to recent data, widely used angiotensin receptor blockers (ARBs) for the treatment of arterial hypertension, also carry a risk of malignancy development. The content of probable carcinogens, such as NDMA or NDEA in the drug valsartan (ARBs), causes the product to be withdrawn from the market. Recent experimental data suggest that another angiotensin receptor blocker-losartan also stimulates cell adhesion and melanoma cell invasion.
CASE REPORT: We present a 70-year-old patient who has been on systemic therapy with a combined drug of amlodipine and valsartan since 2008 and only valsartan from 2015. Three years after the first intake of valsartan (2011), the patient developed a pigment lesion on the right arm. Approximately 2.5 years after doubling the dose of valsartan, the patient observed a progression in the size of the lesion, which was the cause of the dermatological examination and hospitalisation for surgical removal. The melanocytic lesion was removed by radical excision and a surgical field of 0.5 cm in all directions, followed by histological verification, which found the presence of cutaneous melanoma with a tumour thickness of 3 mm. A re-excision was planned with an additional surgical field of 1.5 cm in all directions combined with parallel removal of a draining lymph node.
CONCLUSION: The case is indicative of two things: 1) the possible triggering of melanoma within the systemic treatment with valsartan; and 2) the necessity for optimization of melanoma surgery within the one-step melanoma surgery, which in this case would result in a single surgical excision of the primary lesion, with an operational security field of 2 cm in all directions, along with the removal of a draining lymph node.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Fiala K, Whetteckey J, Manyam V. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord. 2003; 9(6):321-7. https://doi.org/10.1016/S1353-8020(03)00040-3
Tchernev G, Lozev I, Temelkova I, Chernin S, Yungareva I. Schizophrenia as Potential Trigger for Melanoma Development and Progression! The Psycho-Neuro-Endocrine-Oncology (P.N.E.O) Network! Open Access Maced J Med Sci. 2018; 6(8):1442-1445. https://doi.org/10.3889/oamjms.2018.276
Orrell K, Cices , Guido N, Majewski S, Ibler E, Huynh T, Rangel S, Laumann A, Martini M, Rademaker A, West D, Nardone B. Malignant melanoma associated with chronic once daily aspirin exposure in males: a large, single-center, urban, U.S. patient population cohort study from the Research on Adverse Drug events And Reports (RADAR) project. J Am Acad Dermatol. 2018. pii: S0190-9622(18)30485-7.
Sipahi I, Debanne S, Rowland D, Simon D, Fang J. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7):627-36. https://doi.org/10.1016/S1470-2045(10)70106-6
Olschewski D, Hofschröer V, Nielsen N, Seidler D, Schwab A, Stock C. The Angiotensin II Type 1 Receptor Antagonist Losartan Affects NHE1-Dependent Melanoma Cell Behavior. Cell Physiol Biochem. 2018; 45:2560-2576. https://doi.org/10.1159/000488274 PMid:29558744
D'Arrigo T. FDA issues statement as valsartan recalls grow. AphA, September 4, 2018. Retrieved from https://www.pharmacist.com/article/fda-issues-statement-valsartan-recalls-grow
Shanley A. After Valsartan Recalls, Regulators Grapple with Nitrosamine Contamination in APIs.
WJZ. CBS Baltimore. FDA Recalls Common Blood Pressure Medicine Due To Cancer Concerns, 2018.
Wendling P. More Drug Makers Tagged as Valsartan Recall Grows. WebMD, August 13, 2018.
Howard J. Valsartan recall: 4 things patients should know. CNN, August 28, 2018.
Herman A. Another Potential Carcinogen Found in Valsartan. NEJM Journal Watch, September 17, 2018.
Analysis of NDMA levels in recalled valsartan in the U.S., July 30, 2018.
Swetter S, Geller A, Kirkwood J. Melanoma in the older person. Oncology (Williston Park). 2004; 18(9):1187-96.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Georgi Tchernev, Ivanka Temelkova
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
